The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated OS of patients with AL amyloidosis after CAEL-101.
 
Michael Sang Hughes
No Relationships to Disclose
 
Samuel M Pan
No Relationships to Disclose
 
Rajshekhar Chakraborty
Consulting or Advisory Role - Adaptive Biotechnologies; Janssen; Sanofi Pasteur
 
Jayant Raikhelkar
No Relationships to Disclose
 
Mathew Maurer
Consulting or Advisory Role - Alnylam; Eidos Therapeutics; Intellia Therapeutics; Ionis Pharmaceuticals
Research Funding - Alnylam; Eidos Therapeutics; Ionis Pharmaceuticals; Pfizer
 
Markus Y. Mapara
Stock and Other Ownership Interests - Caelum Biosciences (I)
Honoraria - Incyte; Ossium Health
Consulting or Advisory Role - Ossium Health
Research Funding - Ossium Health
Patents, Royalties, Other Intellectual Property - Caelum Biosciences (I)
 
Andrew Eisenberger
No Relationships to Disclose
 
Suzanne Lentzsch
Leadership - Caelum Biosciences
Stock and Other Ownership Interests - Caelum Biosciences
Consulting or Advisory Role - Adaptive Biotechnologies; BMS; GlaxoSmithKline; Janssen; Natera; Oncopeptides; Pfizer; Sanofi; Takeda
Speakers' Bureau - BioAscent; Clinical Care Options; PeerView; RedMedEd.com
Research Funding - Sanofi
Patents, Royalties, Other Intellectual Property - Patent 11-1F4 mAb for use in AL Amyloidosis
 
Divaya Bhutani
Consulting or Advisory Role - Sanofi
Research Funding - Sanofi (Inst)